Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacifi

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,250	118 Pages	Polaris Market Research & Consulting LLP	October, 2024	PLRS19311929

Best Price Guarantee
Price	from $4,250
Length	118 Pages
Publisher	Polaris Market Research & Consulting LLP
Published Date	October, 2024
SKU	PLRS19311929

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 7.81 billion by 2034, according to a new study by Polaris Market Research. The report “Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The idiopathic pulmonary fibrosis treatment market is significantly driven by changing lifestyle habits, such as rising smoking consumption and sedentary behavior, as well as increasing exposure to pollutants. These factors contribute to the rising incidence of lung diseases, including IPF, as poor air quality and unhealthy habits impact respiratory health. Additionally, the growing awareness of idiopathic pulmonary fibrosis and its risk factors encourages earlier diagnosis and treatment. As lifestyles continue to evolve, the demand for effective idiopathic pulmonary fibrosis therapies is expected to rise in the coming years.

The rising prevalence of idiopathic pulmonary fibrosis is driving the growth of the idiopathic pulmonary fibrosis treatment market. According to the National Institutes of Health, the prevalence of idiopathic pulmonary fibrosis was 36 cases per 100,000 people in 2021. The growing awareness and improving diagnostic methods facilitate earlier disease identification, expanding the patient population seeking treatment. Consequently, the combination of increasing idiopathic pulmonary fibrosis prevalence and advancements in diagnostics is significantly boosting demand for effective treatment options, positively impacting the market growth.

The growing number of geriatrics worldwide is expected to significantly drive the idiopathic pulmonary fibrosis treatment market during the forecast period, as older adults are particularly susceptible to the disease. In the European Union, over 21.3% of the population is aged 65 and older, highlighting the increasing demand for effective treatments. This demographic trend will likely lead to a substantial rise in the need for idiopathic pulmonary fibrosis therapies.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights

Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.
By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.
In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure
The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.
A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

Polaris Market Research has segmented the idiopathic pulmonary fibrosis treatment market report on the basis of drug class, route of administration, distribution channel, and region:

By Drug Class Outlook (Revenue – USD Billion, 2020–2034)

Pirfenidone

Nintedanib

Interferon Gammato1b

Others

By Route of Administration (Revenue – USD Billion, 2020–2034)

Oral

Injectable

Others

By Distribution Channel (Revenue – USD Billion, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

US
Canada

Europe

Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe

Asia Pacific

China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific

Latin America

Argentina
Brazil
Mexico
Rest of Latin America

Middle East & Africa

UAE
Saudi Arabia
Israel
South Africa
Rest of MEA

1. Introduction: 1.1. Report Description; 1.1.1. Objectives of the Study; 1.1.2. Market Scope; 1.1.3. Assumptions; 1.2. Stakeholders
2. Executive Summary: 2.1. Market Highlights
3. Research Methodology: 3.1. Overview; 3.1.1. Data Mining; 3.2. Data Sources; 3.2.1. Primary Sources; 3.2.2. Secondary Sources
4. Global Idiopathic Pulmonary Fibrosis Treatment Market Insights: 4.1. Idiopathic Pulmonary Fibrosis Treatment Market – Market Snapshot; 4.2. Idiopathic Pulmonary Fibrosis Treatment Market Dynamics; 4.2.1. Drivers and Opportunities; 4.2.1.1. Rising Geriatric Population Are Driving Market Growth; 4.2.1.2. Advancement in Diagnostic Methods is Propelling Market Size; 4.2.2. Restraints and Challenges; 4.2.2.1. Limited Treatment Options; 4.3. Porter’s Five Forces Analysis; 4.3.1. Bargaining Power of Suppliers (Moderate); 4.3.2. Threats of New Entrants: (Low); 4.3.3. Bargaining Power of Buyers (Moderate); 4.3.4. Threat of Substitute (Moderate); 4.3.5. Rivalry among existing firms (High); 4.4. PESTEL Analysis; 4.5. Idiopathic Pulmonary Fibrosis Treatment Market Trends; 4.6. Value Chain Analysis; 4.7. COVID-19 Impact Analysis
5. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class: 5.1. Key Findings; 5.2. Introduction; 5.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 5.3. Pirfenidone; 5.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Pirfenidone, by Region, 2020-2034 (USD billion); 5.4. Nintedanib; 5.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Nintedanib, by Region, 2020-2034 (USD billion); 5.5. Interferon Gammato1b; 5.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Interferon Gammato1b, by Region, 2020-2034 (USD billion); 5.6. Others; 5.6.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)
6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration: 6.1. Key Findings; 6.2. Introduction; 6.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 6.3. Oral; 6.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Oral, by Region, 2020-2034 (USD billion); 6.4. Injectable; 6.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Injectable, by Region, 2020-2034 (USD billion); 6.5. Others; 6.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)
7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel: 7.1. Key Findings; 7.2. Introduction; 7.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 7.3. Hospital Pharmacies; 7.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD billion); 7.4. Retail Pharmacies; 7.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Retail Pharmacies, by Region, 2020-2034 (USD billion); 7.5. Others; 7.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)
8. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Geography: 8.1. Key Findings; 8.2. Introduction; 8.2.1. Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion); 8.3. Idiopathic Pulmonary Fibrosis Treatment Market – North America; 8.3.1. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.3.2. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.3.3. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.3.4. Idiopathic Pulmonary Fibrosis Treatment Market – U.S.; 8.3.4.1. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.3.4.2. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.3.4.3. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.3.5. Idiopathic Pulmonary Fibrosis Treatment Market – Canada; 8.3.5.1. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.3.5.2. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.3.5.3. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4. Idiopathic Pulmonary Fibrosis Treatment Market – Europe; 8.4.1. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.2. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.3. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.4. Idiopathic Pulmonary Fibrosis Treatment Market – UK; 8.4.4.1. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.4.2. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.4.3. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.5. Idiopathic Pulmonary Fibrosis Treatment Market – France; 8.4.5.1. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.5.2. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.5.3. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.6. Idiopathic Pulmonary Fibrosis Treatment Market – Germany; 8.4.6.1. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.6.2. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.6.3. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.7. Idiopathic Pulmonary Fibrosis Treatment Market – Italy; 8.4.7.1. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.7.2. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.7.3. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.8. Idiopathic Pulmonary Fibrosis Treatment Market – Spain; 8.4.8.1. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.8.2. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.8.3. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.9. Idiopathic Pulmonary Fibrosis Treatment Market – Netherlands; 8.4.9.1. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.9.2. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.9.3. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.10. Idiopathic Pulmonary Fibrosis Treatment Market – Russia; 8.4.10.1. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.10.2. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.10.3. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.4.11. Idiopathic Pulmonary Fibrosis Treatment Market – Rest of Europe; 8.4.11.1. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.4.11.2. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.4.11.3. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5. Idiopathic Pulmonary Fibrosis Treatment Market – Asia Pacific; 8.5.1. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.2. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.3. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.4. Idiopathic Pulmonary Fibrosis Treatment Market – China; 8.5.4.1. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.4.2. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.4.3. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.5. Idiopathic Pulmonary Fibrosis Treatment Market – India; 8.5.5.1. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.5.2. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.5.3. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.6. Idiopathic Pulmonary Fibrosis Treatment Market – Malaysia; 8.5.6.1. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.6.2. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.6.3. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.7. Idiopathic Pulmonary Fibrosis Treatment Market – Japan; 8.5.7.1. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.7.2. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.7.3. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.8. Idiopathic Pulmonary Fibrosis Treatment Market – Indonesia; 8.5.8.1. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.8.2. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.8.3. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.9. Idiopathic Pulmonary Fibrosis Treatment Market – South Korea; 8.5.9.1. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.9.2. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.9.3. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.10. Idiopathic Pulmonary Fibrosis Treatment Market – Australia; 8.5.10.1. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.10.2. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.10.3. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.5.11. Idiopathic Pulmonary Fibrosis Treatment Market – Rest of Asia Pacific; 8.5.11.1. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.5.11.2. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.5.11.3. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.6. Idiopathic Pulmonary Fibrosis Treatment Market – Middle East & Africa; 8.6.1. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.6.2. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.6.3. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.6.4. Idiopathic Pulmonary Fibrosis Treatment Market – Saudi Arabia; 8.6.4.1. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.6.4.2. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.6.4.3. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.6.5. Idiopathic Pulmonary Fibrosis Treatment Market – UAE; 8.6.5.1. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.6.5.2. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.6.5.3. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.6.6. Idiopathic Pulmonary Fibrosis Treatment Market – Israel; 8.6.6.1. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.6.6.2. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.6.6.3. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.6.7. Idiopathic Pulmonary Fibrosis Treatment Market – South Africa; 8.6.7.1. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.6.7.2. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.6.7.3. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.6.8. Idiopathic Pulmonary Fibrosis Treatment Market – Rest of Middle East & Africa; 8.6.8.1. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.6.8.2. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.6.8.3. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.7. Idiopathic Pulmonary Fibrosis Treatment Market – Latin America; 8.7.1. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.7.2. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.7.3. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.7.4. Idiopathic Pulmonary Fibrosis Treatment Market – Mexico; 8.7.4.1. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.7.4.2. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.7.4.3. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.7.5. Idiopathic Pulmonary Fibrosis Treatment Market – Brazil; 8.7.5.1. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.7.5.2. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.7.5.3. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.7.6. Idiopathic Pulmonary Fibrosis Treatment Market – Argentina; 8.7.6.1. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.7.6.2. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.7.6.3. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion); 8.7.7. Idiopathic Pulmonary Fibrosis Treatment Market – Rest of Latin America; 8.7.7.1. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion); 8.7.7.2. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion); 8.7.7.3. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
9. Competitive Landscape: 9.1. Expansion and Acquisition Analysis; 9.1.1. Expansion; 9.1.2. Acquisitions; 9.2. Partnerships/Collaborations/Agreements/Exhibitions; 10. Company Profiles; 10.1. F. Hoffmann-La Roche Ltd; 10.1.1. Company Overview; 10.1.2. Financial Performance; 10.1.3. Product Benchmarking; 10.1.4. Recent Development; 10.2. Boehringer Ingelheim International GmbH; 10.2.1. Company Overview; 10.2.2. Financial Performance; 10.2.3. Product Benchmarking; 10.2.4. Recent Development; 10.3. Bristol-Myers Squibb Company; 10.3.1. Company Overview; 10.3.2. Financial Performance; 10.3.3. Product Benchmarking; 10.3.4. Recent Development; 10.4. Medicinova, Inc; 10.4.1. Company Overview; 10.4.2. Financial Performance; 10.4.3. Product Benchmarking; 10.4.4. Recent Development; 10.5. Merck & Co., Inc.; 10.5.1. Company Overview; 10.5.2. Financial Performance; 10.5.3. Product Benchmarking; 10.5.4. Recent Development; 10.6. Galapagos NV; 10.6.1. Company Overview; 10.6.2. Financial Performance; 10.6.3. Product Benchmarking; 10.6.4. Recent Development; 10.7. Novartis AG; 10.7.1. Company Overview; 10.7.2. Financial Performance; 10.7.3. Product Benchmarking; 10.7.4. Recent Development; 10.8. Fibrogen, Inc.; 10.8.1. Company Overview; 10.8.2. Financial Performance; 10.8.3. Product Benchmarking; 10.8.4. Recent Development; 10.9. Avalyn Pharma Inc.; 10.9.1. Company Overview; 10.9.2. Financial Performance; 10.9.3. Product Benchmarking; 10.9.4. Recent Development; 10.10. Promedior, Inc.; 10.10.1. Company Overview; 10.10.2. Financial Performance; 10.10.3. Product Benchmarking; 10.10.4. Recent Development